Top Biotech Stocks To Buy For 2019

On Friday, our Elite Opportunity Pronewsletter suggested small cap specialty pharmaceuticalstock BioDelivery Sciences International (NASDAQ: BDSI) as a bullish/long trade:

Fundamentally, BDSI isn’t the most attractive prospect right now, but when you consider how many of these small biotech stocks play out their lives as public companies, it sure looks like a bottom has been put in, one that could end up serving as a catapult for major brokerage firms looking to gun the stock higher, and then do another subsequent capital raise at much higher levels.”

“I’ve included a daily chart of the stock below, and as you can see, I’ve circled its recent price action, which clearly looks like a strong reversal could be in the making right now. Assuming the stock doesn’t breach its recent lows, the recent buying interest also suggests we could be in the early stages of a much stronger move to the upside.

Top Biotech Stocks To Buy For 2019: Superior Drilling Products, Inc.(SDPI)

Advisors’ Opinion:

  • [By Money Morning News Team]

    Superior Drilling Products Inc.(NYSE: SDPI) is based in Utah and manufactures equipment used in drilling for the natural gas and oil mining sectors.

Top Biotech Stocks To Buy For 2019: Alpine Total Dynamic Dividend Fund(AOD)

Advisors’ Opinion:

  • [By Logan Wallace]

    Oppenheimer & Co. Inc. lifted its stake in shares of Alpine Total Dynamic Div (NYSE:AOD) by 14.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 101,451 shares of the investment management company’s stock after acquiring an additional 12,551 shares during the period. Oppenheimer & Co. Inc. owned 0.09% of Alpine Total Dynamic Div worth $906,000 as of its most recent SEC filing.

Top Biotech Stocks To Buy For 2019: Infinera Corporation(INFN)

Advisors’ Opinion:

  • [By Evan Niu, CFA]

    Shares of Infinera (NASDAQ:INFN) have rebounded today, up by 8% as of 3 p.m. EDT, following a sell-off yesterdaythat came in response to first-quarter earnings. Investors may realize they overreacted.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    MDC Partners Inc. (NASDAQ: MDCA) fell 23.4 percent to $5.25 in pre-market trading after a first-quarter earnings miss.
    Hudson Technologies Inc. (NASDAQ: HDSN) shares fell 15.1 percent to $3.48 in pre-market trading after the company reported downbeat Q1 earnings.
    Nuance Communications, Inc. (NASDAQ: NUAN) fell 14 percent to $13.15 in pre-market trading after the company posted downbeat Q2 earnings and lowered FY18 organic growth guidance.
    Myomo, Inc. (NYSE: MYO) fell 13.2 percent to $3.10 in pre-market trading after reporting downbeat quarterly results.
    Rowan Companies plc (NYSE: RDC) shares fell 10.7 percent to $14.13 in pre-market trading after climbing 8.50 percent on Wednesday.
    BT Group plc (NYSE: BT) fell 9 percent to $14.80 in pre-market trading after the company reported Q4 results and announced plans to cut 13,000 jobs over the next three years.
    Exelixis, Inc. (NASDAQ: EXEL) fell 8.3 percent to $19.90 in pre-market trading after the company disclosed that IMblaze370 Phase 3 pivotal trial of atezolizumab and cobimetinib in patients with heavily pretreated locally advanced or metastatic colorectal cancer did not meet primary endpoint.
    Infinera Corporation (NASDAQ: INFN) fell 8.2 percent to $10.80 in pre-market trading after reporting Q1 results.
    Synaptics, Incorporated (NASDAQ: SYNA) shares fell 7.4 percent to $43.00 in pre-market trading. Synaptics reported better-than-expected earnings for its third quarter, while sales missed estimates.
    Randgold Resources Limited (NASDAQ: GOLD) shares fell 7.4 percent to $76.23 in pre-market trading after reporting Q1 earnings.
    Integra LifeSciences Holdings Corporation (NASDAQ: IART) shares fell 7 percent to $59.36 in pre-market trading. Integra LifeSciences priced its 5.25 million share public offering of common stock at $58.50 per share.
    Array BioPharma Inc. (NASDAQ: ARRY) shares fell 6.9 percent to $12.75 in pre-m

  • [By Brian Feroldi]

    Infinera (NASDAQ:INFN)reported its first-quarter results on Wednesday, May 9. Management at the optical equipment provider told investors last quarter that revenueand margins were starting to rebound nicely from their 2017 lows. But did the company keep its momentum up in the first-quarter?Let’s dig into the numbers to find out.

  • [By Max Byerly]

    Infinera (NASDAQ:INFN) was the recipient of unusually large options trading activity on Thursday. Stock investors bought 3,256 put options on the company. This is an increase of approximately 841% compared to the typical daily volume of 346 put options.

Leave a Reply

Your email address will not be published. Required fields are marked *